ArticleNeurosurgical review2025
Potential for multidrug combination therapy in patients with World Federation of Neurological Surgeons grade V subarachnoid hemorrhage.
Article in Neurosurgical review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with World Federation of Neurological Surgeons (WFNS) grade V aneurysmal subarachnoid hemorrhage (SAH) have poor outcomes, and no effective pharmacological treatment has been established. This study aimed to investigate whether any of the drugs currently used in Japan, where nimodipine is not approved, are effective for WFNS grade V SAH patients. From a database of SAH patients prospectively enrolled at nine hospitals in Japan between 2013 and 2024, 297 patients (mean age, 67.3 years) who underwent microsurgical or endovascular treatment for ruptured aneurysms and had WFNS grade V SAH at admission were retrospectively analyzed. Cerebral vasospasm and delayed cerebral infarction occurred in 68 (22.9%) and 43 (14.5%) patients, respectively. Rescue therapy was performed in 34 patients (11.4%), and 3-month good outcomes (modified Rankin scale [mRS] 0-3) were achieved in 91 patients (30.6%). Multivariate analyses revealed that pre-onset mRS 1-2, admission modified Fisher grade 4, ruptured middle cerebral artery aneurysm, acute hydrocephalus, and older age were independently associated with poor outcomes, while combination drug therapy with fasudil hydrochloride (Rho-kinase inhibitor) + cilostazol (phosphodiesterase type III inhibitor) + eicosapentaenoic acid (omega-3 polyunsaturated fatty acid) or clazosentan (endothelin receptor subtype A antagonist) + cilostazol was the only independent determinant of good outcomes. The combination drug therapies were also independent inhibitors of delayed cerebral infarction (non-iatrogenic cerebral infarction on computed tomography after SAH), but not of cerebral vasospasm (≥ 50% angiographic vasospasm of a major cerebral artery) and rescue therapy (endovascular treatment and hyperdynamic therapy for delayed ischemic symptoms with and without vasospasm). This study suggested that the triple or dual drug therapy may contribute to improved outcomes in patients with WFNS grade V by suppressing vasospasm-unrelated pathologies rather than cerebral vasospasm itself, warranting further study.
Indexed as
Identifiers
41269360What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.